Neurocrine Biosciences, Inc.
Kyle Gano (Chief Executive Officer) reports NBIX insider transactions
About this filing
Neurocrine Biosciences, Inc. (NBIX) filed Form 4 (insider transaction) with the SEC on Nov 3, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Kyle Gano · Chief Executive Officer, Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 1, 2026 | M · exercise or conversion of a derivative | +614 | $0.00 | $0.00 | 155,342 | Direct |
| Nov 1, 2026 | F · tax withholdingFootnotes F1 | −332 | $146.10 | $48,505.20 | 155,010 | Direct |
| Nov 1, 2026 | M · exercise or conversion of a derivativeRestricted Stock UnitFootnotes F2, F3 | −614 | $0.00 | $0.00 | 1,228 | Direct |
Footnotes
- F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
- F2 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F3 This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, vested as to 614 shares on November 1, 2026 and will vest as to 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award.
More NBIX filings
- 4
Filed Nov 19, 2026
- 144
Filed Nov 17, 2026
- 144
Filed Nov 10, 2026
- 4
Filed Nov 5, 2026
- 4
Filed Nov 3, 2026
- 144
Filed Nov 2, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.